Navigation Links
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
Date:12/17/2009

='External Link';s.eVar3=s.prop5;s.prop15='79490252';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.anadyspharma.com/">www.anadyspharma.com. A telephone replay with slides will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 75270153. The webcast and telephone replay will be available through December 31, 2009.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) the expected timing for enrolling the next cohort in the ANA598 Phase II study and for receiving 12 week data from the 200 mg bid cohort and 4 and 12 week data from the 400 mg bid cohort; (ii) the prospects of ANA598 being able to contribute to long-term treatment outcome as measured by SVR and the hope that ANA598 will be established as the leading non-nucleoside in HCV, suitable for combination with current SOC as well as with other direct antivirals currently in development; (iii) the ability for patients to achieve EVR and SVR in the ANA598 Phase II study; and (iv) assessments of the safety and tolerability profile of ANA598 based on the interim 4 week analysis. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 will not have unforeseen safety issues or will continue to have favorable results as the Phase II trial progresses. In addition, Anadys' results may be affected by competition from other biotechno
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
11. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 Fuse Science, Inc. (OTCQB: DROP), ... that is developing new, patent-pending technologies poised to redefine how ... it will hold a business update teleconference and webcast for ... , 2013 at 4:30 PM ET. Fuse ... host the call and will be joined by ...
(Date:5/17/2013)... , May 17, 2013  PENTAX Medical, a ... Medical, a global leader in ultrasound imaging, recently ... companies to enable further innovation in the development ... Hitachi-Aloka ultrasound systems and PENTAX Medical endoscopic portfolio ... families of EUS systems. This agreement will continue ...
(Date:5/17/2013)... 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 inhibitor ... both dose groups. The primary endpoint assessed the proportion ... with data reported in previous trials, the most common ... results will be presented at an upcoming medical congress. ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 2PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
... Amsterdam Molecular,Therapeutics (AMT) and Progenika Biopharma announced today ... agreement for,LPLchip(TM), a diagnostic tool to rapidly diagnose patients ... developed Glybera(R) as,a gene therapy for patients with this ... this year AMT announced new clinical data showing that ...
... , CHAPEL HILL, N.C., Oct. 29 Cempra Pharmaceuticals ... CEM-101, at the Infectious Diseases Society of America, 47th ... Philadelphia. , Susceptibility of CEM-101 and more than 25 ... pneumoniae strains collected in 2008 from medical centers ...
Cached Medicine Technology:AMT Starts Development LPLChip(TM) With Progenika 2AMT Starts Development LPLChip(TM) With Progenika 3Data Presented on Cempra Pharmaceutical's CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates 2
(Date:5/17/2013)... Spring floods, summer droughts and temperature ... who tend them. Help gardens recover from the crazy ... year. Myers suggests the following steps to revive ... by assessing the current condition of the landscape. Remove ... insect and disease organisms that can infest healthy plantings. ...
(Date:5/17/2013)... & Johnson subsidiary DePuy Orthopaedics announced on May 16 ... This comes after the company saw the market for ... increased regulation,** and after the 2010 recall of the ... a metal-on-metal hip implant law firm, applauds the decision ... that it maintains a comprehensive website at http://www.hipreplacementlawsuitcenter.com ...
(Date:5/17/2013)... Charlotte’s top professional athletes and local heroes are ... the Muscular Dystrophy Association at the annual Charlotte ... Bank of America Stadium from 6-10 p.m. , ... pairs top professional athletes and local heroes, including military ... local child living with a neuromuscular disease) for ...
(Date:5/17/2013)... Cleveland, OH (PRWEB) May 17, 2013 ... nosings are an eye-catching, resilient, slip-resistant renovation ... surface. Designed for new construction or staircase renovation ... and durability while providing a look to compliment ... industrial applications, but attractive enough for home stairs ...
(Date:5/17/2013)... -- Alcoholics who smoke have more problems with ... who are nonsmokers, researchers have found. This ... time, according to the study published online May ... Alcoholism: Clinical & Experimental Research . ... "The independent and interactive effects of smoking and ...
Breaking Medicine News(10 mins):Health News:Garden Revival: Gardening Expert Melinda Myers Shares Tips for Helping Gardens Recover From Extreme Weather Conditions 2Health News:Garden Revival: Gardening Expert Melinda Myers Shares Tips for Helping Gardens Recover From Extreme Weather Conditions 3Health News:DePuy Announces It Will Stop Selling Metal-On-Metal Hip Implants, Notes Rottenstein Law Group LLP 2Health News:DePuy Announces It Will Stop Selling Metal-On-Metal Hip Implants, Notes Rottenstein Law Group LLP 3Health News:MDA Hosts Annual Charlotte Muscle Team Event 2Health News:MDA Hosts Annual Charlotte Muscle Team Event 3Health News:New Bold Step Renovation Stair Treads and Nosings from Martinson-Nicholls Add Slip Resistance to Stairs 2Health News:Alcoholics Who Smoke May Face Early Brain Aging 2Health News:Alcoholics Who Smoke May Face Early Brain Aging 3
... statins to patients with diastolic heart failure increases// the ... drugs. ,William C. Little and his research ... with diastolic heart failure (DHF) treated with statins has ... diastolic heart failure patients published in the Journal Circulation: ...
... July 23 Prime Minister Manmohan Singh today said ... measures and coercion of any control to achieve ... first meeting of the reconstituted National Commission on ... strategy focusing on the welfare of women and ...
... Pre-eclampsia is a disease that causes high blood pressure in ... death of mother and infant in the world. Now a ... women who are likely to develop the problem. ... "We're really excited about this finding," said Clifford Librach, a ...
... can severely affect brain functions like learning and impulsive behavior.// ... latest issue of New Scientist, said that it would help ... ., ,Neuroscientists Yuriori Goto and his team at the ... stimulated the two different regions of the brain in a ...
... who are training for marathon running events may be ... from low levels of sodium in the body. The ... drink excess amounts of fluids during exercises. ,Awareness ... professionals need reliable information on the causes, recognition, prevention, ...
... Buffalo, has found that Post-menopausal// women has an increased chance ... Journal of Periodontology, which was conducted in 106 Post-menopausal women ... 57.5% of the women in the study lost at least ... loss in Post-menopausal women, as studies has proved that loss ...
Cached Medicine News:Health News:Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients 2Health News:Prime Minister Manmohan Against Incentive-Based Population Control 2Health News:Prime Minister Manmohan Against Incentive-Based Population Control 3Health News:Revolutionary Simple Pregnancy Blood Test Can Save Both Mother And Child 2Health News:Regular Use Of Cocaine Can Impair Brain Functions 2Health News:Athletes Warned Of Exercise-Associated Hyponatremia 2Health News:Post-Menopausal Status May Cause Tooth Decay 2
...
... is a cutting-edge ECG management ... functionality and convenient, web-based access ... and information technology (IT) benefits, ... costs, and improved patient care. ...
... Philips' Zymed 2010 plus Holter Software ... analysis application as easy to install, ... processorwith data presentation as comprehensive as ... prospective superimposition, prospective paging and QuickScan, ...
... tiny, water-resistant monitor captures the data you ... ,Requiring only five electrodes, the DigiTrak ... the entire patient test, which can be ... AA battery. Three channels of ECG recording ...
Medicine Products: